1. Porcine recombinant factor VIII (Obizur; OBI-1; BAX801): product characteristics and preclinical profile
- Author
-
A. Schiviz, F. Horling, Pete Lollar, W. Hoellriegl, P. Wojciechowski, C. K. Lai, C. Apostol, C. Piskernik, and David Lillicrap
- Subjects
business.industry ,Immunogenicity ,Hamster ,Hematology ,General Medicine ,030204 cardiovascular system & hematology ,Pharmacology ,Blood proteins ,Genetically modified organism ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Pharmacokinetics ,Tolerability ,law ,Recombinant DNA ,Medicine ,Animal studies ,business ,Genetics (clinical) ,030215 immunology - Abstract
Introduction Acquired haemophilia A (AHA) is a rare, often severe, auto-immune bleeding disorder caused by the development of inhibitory antibodies (inhibitors) to factor VIII (FVIII). Bypassing agents, recombinant activated FVII or activated prothrombin complex concentrate, are currently recommended as first-line treatments to control bleeding events in patients with AHA. Aim A plasma-derived porcine FVIII (Hyate:C, Ipsen, UK) was used as a first-line treatment for AHA but was discontinued in 2004 due to viral safety concerns. A recombinant pFVIII (rpFVIII), Obizur (OBI-1; BAX801), which is expected to have a similar efficacy profile to Hyate:C but with a superior safety profile was developed and recently approved by the US Food and Drug Administration for the treatment of AHA. Methods Obizur manufacturing begins with the expression of B domain deleted rpFVIII by genetically modified baby hamster kidney-derived cells. The final purified and lyophilized drug product has a negligible risk of viral contamination and contains no animal-derived plasma proteins. Obizur was evaluated for immunogenicity, tolerability, pharmacokinetics and bleeding times in preclinical models including in haemophiliac dogs, cynomolgus monkeys and FVIII-knockout mice. Results Preclinical animal studies show that the efficacy and immunogenicity of Obizur are similar to that of Hyate:C and that Obizur has a more favourable safety profile. Conclusions Obizur is a highly purified recombinant porcine FVIII drug product that has been demonstrated to have a favourable safety and efficacy profile when compared with Hyate:C and can be a valuable treatment option for control of bleeding in AHA patients.
- Published
- 2015
- Full Text
- View/download PDF